30 years after MS was first treatable, challenges remain amid triumphs
It’s been three decades since the first treatment for multiple sclerosis (MS) was approved. In that time, the field…
Articles by Marisa Wexler, MS
DDX39B seen as ‘guardian’ in autoimmune attacks that drive MS
The protein DDX39B is a master regulator of immune tolerance, or the immune system’s ability to distinguish self from potentially…
Aerobic, resistance exercises most effective for patient fitness: Study
For people with multiple sclerosis (MS), all forms of exercise are likely to be beneficial for physical fitness, but…
Molecular mechanisms help drive microglia problems in brain in MS
Disease-associated inflammatory activity of microglia — a type of immune cell with a central role in the development of…
Researchers analyze switching to Kesimpta from oral therapies
People with relapsing multiple sclerosis (MS) who experienced disease activity while on oral therapies had less disease activity after…
Novel immune cell strategy found to reverse disease in MS mice
Microparticles that activate regulatory T-cells, or Tregs, an immune cell type with anti-inflammatory properties, reversed the accumulation of physical disability…
Analyses of protein levels in blood can help ID MS patient subgroups
Analyses of protein levels in the blood can be used to identify groups of multiple sclerosis (MS) patients with…
Vidofludimus calcium tolerated well for nearly 4 years
Long-term treatment with vidofludimus calcium (IMU-838) has been tolerated well overall among people with relapsing-remitting MS (RRMS), new…
Briumvi approved in Europe for active, relapsing forms of MS
The European Commission has approved Briumvi (ublituximab) for the treatment of adults with relapsing forms of multiple sclerosis…
Average MS relapse rate lower than in past decades: UK study
The average rate of relapses for multiple sclerosis (MS) in the modern era is lower than it has been…
Cannabis oral spray nabiximols found to ease spasticity in MS
Treatment with the cannabis oral spray nabiximols helped to relieve spasticity — increased muscle stiffness and spasms common in…
Stem cell therapy may be better than some DMTs for highly active RRMS
Stem cell therapy is better than Gilenya (fingolimod) or Tysabri (natalizumab) at reducing relapse rates and easing disability…
New study gives snapshot of MS in US by race, age, sex, location
An updated snapshot of multiple sclerosis (MS) in the U.S. — provided by new population estimates from a study…
New study data may help explain EBV and MS link
When the immune system launches an attack to fight off infection with the Epstein-Barr virus, immune cells can accidentally…
Stem cell therapy may do most good when given early
People with multiple sclerosis (MS) who have never received treatment with a disease-modifying therapy tend to have better…
Tadpole model could be launchpad to test therapies for remyelination
A newly developed laboratory model using tadpoles can help determine the remyelinating potential of new multiple sclerosis (MS) therapies…
High NfL levels seen in children near times of disease activity: Study
Blood levels of the nerve damage marker NfL seem to spike to very high levels around times of disease activity…
Virtual reality therapy can improve balance in patients: Meta-analysis
Rehabilitation therapy that utilizes virtual reality can help to improve balance and reduce the fear of falling for people with…
AAN 2023: Early use of Ocrevus lowers disease activity in relapsing MS
Nearly half of the people with relapsing forms of multiple sclerosis (MS) treated early with Ocrevus (ocrelizumab) in…
AAN 2023: MS disability not worse for most on Kesimpta over 5 years
More than 80% of patients with relapsing forms of multiple sclerosis (MS) given Kesimpta (ofatumumab) continuously for up…
AAN 2023: Low rates of disease activity after stem cell transplant
There was no evidence of multiple sclerosis (MS) disease activity for at least two years in patients who underwent…
AAN 2023: No relapses on Ocrevus for 90% of Black, Hispanic patients
More than 90% of Black and Hispanic patients with multiple sclerosis (MS) treated with Ocrevus (ocrelizumab) in a…
AAN 2023: Aubagio reduced risk of developing MS symptoms in RIS trial
Treatment with Aubagio (teriflunomide) significantly reduces the risk that adults with radiologically isolated syndrome (RIS) will develop symptoms of…
AAN 2023: TUDCA supplements lower inflammatory cell counts in progressive MS trial
Supplements with tauroursodeoxycholic acid (TUDCA) were generally well tolerated among people with progressive forms of multiple sclerosis (MS), according…
AAN 2023: MSC-NP aids walking in advanced progressive MS patients
Use of the cell therapy MSC-NP failed to show a significant effect on overall disability scores among people with progressive…
Possible treatment target in myelin damage, inflammation pathway
Damage to the myelin sheath, a hallmark feature of multiple sclerosis (MS), leads to increased levels of fatty molecules…
AAN 2023: MS therapies don’t seem to raise pregnancy complications
Most treatments for multiple sclerosis (MS) are not associated with an increased risk of complications during pregnancy, according to…
Secondary progressive MS found to start later, move slower than PPMS
People with secondary progressive multiple sclerosis (SPMS) seem to experience slower worsening of their disabilities than those with the…
New formulation of ibudilast found to ease inflammation in MS mice
A novel formulation of ibudilast, delivered into the nose, was able to reduce inflammation and prevent nerve damage in…
Skin patches may be more convenient MS antibody medicine
Scientists have developed new skin patches that could offer a more convenient and less painful way to administer antibody-based medicines…